Marco van de Weert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6477586/publications.pdf

Version: 2024-02-01

91 papers 5,614 citations

34 h-index 79698 73 g-index

97 all docs 97
docs citations

97 times ranked 7457 citing authors

#	Article	IF	CITATIONS
1	Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharmaceutical Research, 2000, 17, 1159-1167.	3.5	636
2	Fluorescence quenching and ligand binding: A critical discussion of a popular methodology. Journal of Molecular Structure, 2011, 998, 144-150.	3.6	513
3	A Helical Structural Nucleus Is the Primary Elongating Unit of Insulin Amyloid Fibrils. PLoS Biology, 2007, 5, e134.	5.6	229
4	Fourier Transform Infrared Spectrometric Analysis of Protein Conformation: Effect of Sampling Method and Stress Factors. Analytical Biochemistry, 2001, 297, 160-169.	2.4	222
5	Study on the binding of Thioflavin T to \hat{l}^2 -sheet-rich and non- \hat{l}^2 -sheet cavities. Journal of Structural Biology, 2007, 158, 358-369.	2.8	219
6	Forced Degradation of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2012, 101, 895-913.	3.3	207
7	Protein Adsorption at Charged Surfaces: The Role of Electrostatic Interactions and Interfacial Charge Regulation. Langmuir, 2011, 27, 2634-2643.	3.5	205
8	The effect of a water/organic solvent interface on the structural stability of lysozyme. Journal of Controlled Release, 2000, 68, 351-359.	9.9	200
9	Binding mode of Thioflavin T in insulin amyloid fibrils. Journal of Structural Biology, 2007, 159, 483-497.	2.8	193
10	Fluorescence Quenching to Study Protein-ligand Binding: Common Errors. Journal of Fluorescence, 2010, 20, 625-629.	2.5	186
11	Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 65, 10-17.	4.3	159
12	Secondary Nucleation and Accessible Surface in Insulin Amyloid Fibril Formation. Journal of Physical Chemistry B, 2008, 112, 3853-3858.	2.6	137
13	Thermal Dissociation and Unfolding of Insulin. Biochemistry, 2005, 44, 11171-11177.	2.5	119
14	Quality by design – Spray drying of insulin intended for inhalation. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 828-838.	4.3	117
15	Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass $\hat{a} \in \mathbb{C}$ Prediction of viscosity through protein $\hat{a} \in \mathbb{C}$ protein interaction measurements. European Journal of Pharmaceutical Sciences, 2013, 49, 400-410.	4.0	112
16	Identification of Oxidized Methionine in Peptides., 1996, 10, 1905-1910.		111
17	On the purported "backbone fluorescence―in protein three-dimensional fluorescence spectra. RSC Advances, 2016, 6, 112870-112876.	3.6	108
18	Lysozyme distribution and conformation in a biodegradable polymer matrix as determined by FTIR techniques. Journal of Controlled Release, 2000, 68, 31-40.	9.9	105

#	Article	IF	CITATIONS
19	Thioflavin T Hydroxylation at Basic pH and Its Effect on Amyloid Fibril Detection. Journal of Physical Chemistry B, 2008, 112, 15174-15181.	2.6	100
20	Drying methods for protein pharmaceuticals. Drug Discovery Today: Technologies, 2008, 5, e81-e88.	4.0	83
21	A reassessment of synchronous fluorescence in the separation of Trp and Tyr contributions in protein emission and in the determination of conformational changes. Journal of Molecular Structure, 2014, 1077, 68-76.	3.6	82
22	Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. Journal of Controlled Release, 2015, 210, 48-57.	9.9	76
23	Preparing and evaluating delivery systems for proteins. European Journal of Pharmaceutical Sciences, 2006, 29, 174-182.	4.0	70
24	Complex coacervates of hyaluronic acid and lysozyme: Effect on protein structure and physical stability. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 325-331.	4.3	63
25	Stability of Monoclonal Antibodies at High-Concentration: Head-to-Head Comparison of the IgG1 and IgG4 Subclass. Journal of Pharmaceutical Sciences, 2014, 103, 115-127.	3.3	58
26	Characterization of poly(l-lactic acid) microspheres loaded with holmium acetylacetonate. Biomaterials, 2001, 22, 3073-3081.	11.4	53
27	Complex Coacervation of Lysozyme and Heparin: Complex Characterization and Protein Stability. Pharmaceutical Research, 2004, 21, 2354-2359.	3.5	50
28	Characterisation of salmon calcitonin in spray-dried powder for inhalationEffect of chitosan. International Journal of Pharmaceutics, 2007, 331, 176-181.	5.2	49
29	Characterization of a cyclosporine solid dispersion for inhalation. AAPS Journal, 2007, 9, E190-E199.	4.4	48
30	Interfacial Complexes between a Protein and Lipophilic Ions at an Oilâ^'Water Interface. Analytical Chemistry, 2010, 82, 7699-7705.	6.5	47
31	Influence of neutron irradiation on holmium acetylacetonate loaded poly(l-lactic acid) microspheres. Biomaterials, 2002, 23, 1831-1839.	11.4	42
32	Co-encapsulation of lyoprotectants improves the stability of protein-loaded PLGA nanoparticles upon lyophilization. International Journal of Pharmaceutics, 2015, 496, 850-862.	5.2	42
33	Probing Structural Changes of Proteins Incorporated into Water-in-Oil Emulsions. Journal of Pharmaceutical Sciences, 2004, 93, 1847-1859.	3.3	40
34	Characterisation and physical stability of PEGylated glucagon. International Journal of Pharmaceutics, 2007, 330, 89-98.	5.2	40
35	Competitive Adsorption of Monoclonal Antibodies and Nonionic Surfactants at Solid Hydrophobic Surfaces. Journal of Pharmaceutical Sciences, 2015, 104, 593-601.	3.3	37
36	Factors of importance for a successful delivery system for proteins. Expert Opinion on Drug Delivery, 2005, 2, 1029-1037.	5.0	35

#	Article	IF	CITATIONS
37	Chemical and Thermal Stability of Insulin: Effects of Zinc and Ligand Binding to the Insulin Zinc-Hexamer. Pharmaceutical Research, 2006, 23, 2611-2620.	3.5	34
38	Effects of sucrose on rFVIIa aggregation and methionine oxidation. European Journal of Pharmaceutical Sciences, 2004, 21, 597-606.	4.0	33
39	Large-scale polymorphism and auto-catalytic effect in insulin fibrillogenesis. Soft Matter, 2010, 6, 4413.	2.7	33
40	Development of poly(ortho esters) and their application for bovine serum albumin and bupivacaine delivery. Journal of Controlled Release, 2002, 78, 133-141.	9.9	32
41	Effect of the Freezing Step in the Stability and Bioactivity of Protein-Loaded PLGA Nanoparticles Upon Lyophilization. Pharmaceutical Research, 2016, 33, 2777-2793.	3.5	30
42	Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation. International Journal of Pharmaceutics, 2018, 550, 35-44.	5.2	30
43	Mass spectrometric analysis of oxidized tryptophan. Journal of Mass Spectrometry, 1998, 33, 884-891.	1.6	28
44	The Molecular Chaperone α-Crystallin as an Excipient in an Insulin Formulation. Pharmaceutical Research, 2010, 27, 1337-1347.	3.5	27
45	Design of Experiments-Based Monitoring of Critical Quality Attributes for the Spray-Drying Process of Insulin by NIR Spectroscopy. AAPS PharmSciTech, 2012, 13, 747-755.	3.3	26
46	Ligand Binding and Thermostability of Different Allosteric States of the Insulin Zincâ^'Hexamer. Biochemistry, 2006, 45, 4014-4024.	2.5	23
47	Semisolid, Self-Catalyzed Poly(Ortho Ester)s As Controlled-Release Systems: Protein Release and Protein Stability Issues. Journal of Pharmaceutical Sciences, 2002, 91, 1065-1074.	3.3	22
48	Determination of dissociation constants between polyelectrolytes and proteins by affinity capillary electrophoresis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 892-896.	2.3	22
49	Correlation Between Enzyme Activity and Stability of a Protease, an Alphaâ€Amylase and a Lipase in a Simplified Liquid Laundry Detergent System, Determined by Differential Scanning Calorimetry. Journal of Surfactants and Detergents, 2012, 15, 9-21.	2.1	22
50	Studies on human insulin adsorption kinetics at an organic–aqueous interface determined using a label-free electroanalytical approach. Colloids and Surfaces B: Biointerfaces, 2008, 63, 243-248.	5.0	20
51	Multivariate Analysis of Phenol in Freeze-Dried and Spray-Dried Insulin Formulations by NIR and FTIR. AAPS PharmSciTech, 2011, 12, 627-636.	3.3	20
52	Fuzzy Logic-Based Expert System for Evaluating Cake Quality of Freeze-Dried Formulations. Journal of Pharmaceutical Sciences, 2013, 102, 4364-4374.	3.3	20
53	Effect of ethanol as a co-solvent on the aerosol performance and stability of spray-dried lysozyme. International Journal of Pharmaceutics, 2016, 513, 175-182.	5.2	20
54	Protease and Amylase Stability in the Presence of Chelators Used in Laundry Detergent Applications: Correlation Between Chelator Properties and Enzyme Stability in Liquid Detergents. Journal of Surfactants and Detergents, 2012, 15, 265-276.	2.1	18

#	Article	IF	Citations
55	The Effect of Protein PEGylation on Physical Stability in Liquid Formulation. Journal of Pharmaceutical Sciences, 2014, 103, 3043-3054.	3.3	18
56	Mechanistic study of the inhibitory activity of Geum urbanum extract against \hat{l} ±-Synuclein fibrillation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2016, 1864, 1160-1169.	2.3	18
57	Formation of Dielectric Layers and Charge Regulation in Protein Adsorption at Biomimetic Interfaces. Langmuir, 2012, 28, 1804-1815.	3.5	17
58	Small Angle X-ray Scattering-Based Elucidation of the Self-Association Mechanism of Human Insulin Analogue Lys ^{B29} (N ^ε ï‰-carboxyheptadecanoyl) des(B30). Biochemistry, 2013, 52, 282-294.	2.5	17
59	Polysorbate 80 controls Morphology, structure and stability of human insulin Amyloid-Like spherulites. Journal of Colloid and Interface Science, 2022, 606, 1928-1939.	9.4	16
60	Effect of excipients on encapsulation and release of insulin from spray-dried solid lipid microparticles. International Journal of Pharmaceutics, 2018, 550, 439-446.	5.2	15
61	Reversible aggregation of lysozyme in a biodegradable amphiphilic multiblock copolymer. European Journal of Pharmaceutics and Biopharmaceutics, 2002, 54, 89-93.	4.3	14
62	Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. International Journal of Pharmaceutics, 2002, 248, 229-237.	5.2	14
63	Analysis of Insulin Allostery in Solution and Solid State With FTIR. Journal of Pharmaceutical Sciences, 2009, 98, 3265-3277.	3.3	13
64	Rhamnogalacturonan-I Based Microcapsules for Targeted Drug Release. PLoS ONE, 2016, 11, e0168050.	2.5	13
65	Large-Scale Biophysical Evaluation of Protein PEGylation Effects: In Vitro Properties of 61 Protein Entities. Molecular Pharmaceutics, 2016, 13, 1587-1598.	4.6	12
66	Rapid Conformational Analysis of Protein Drugs in Formulation by Hydrogen/Deuterium Exchange Mass Spectrometry. Journal of Pharmaceutical Sciences, 2016, 105, 3269-3277.	3.3	12
67	Taylor Dispersion Analysis as a promising tool for assessment of peptide-peptide interactions. European Journal of Pharmaceutical Sciences, 2016, 93, 21-28.	4.0	12
68	Screening of plants used in the European traditional medicine to treat memory disorders for acetylcholinesterase inhibitory activity and anti amyloidogenic activity. Journal of Ethnopharmacology, 2017, 200, 66-73.	4.1	12
69	Analysis of Protein Physical Stability in Lipid Based Delivery Systemsâ€"The Challenges of Lipid Drug Delivery Systems. Journal of Biomedical Nanotechnology, 2009, 5, 401-408.	1.1	12
70	The Chaperone-like Protein α-Crystallin Dissociates Insulin Dimers and Hexamers. Biochemistry, 2009, 48, 9313-9320.	2.5	11
71	lonic strength-dependent denaturation of Thermomyces lanuginosus lipase induced by SDS. Archives of Biochemistry and Biophysics, 2011, 506, 92-98.	3.0	11
72	Thermal and acid denaturation of bovine lens αâ€erystallin. Proteins: Structure, Function and Bioinformatics, 2011, 79, 1747-1758.	2.6	11

#	Article	IF	Citations
73	Preferential Interactions and the Effect of Protein PEGylation. PLoS ONE, 2015, 10, e0133584.	2.5	10
74	Circular Dichroism Spectroscopy for Structural Characterization of Proteins. Advances in Delivery Science and Technology, 2016, , 223-251.	0.4	9
75	Correlation between calculated molecular descriptors of excipient amino acids and experimentally observed thermal stability of lysozyme. International Journal of Pharmaceutics, 2017, 523, 238-245.	5.2	9
76	Investigation of factors affecting the stability of lysozyme spray dried from ethanol-water solutions. International Journal of Pharmaceutics, 2017, 534, 263-271.	5.2	9
77	Ion-Mediated Morphological Diversity in Protein Amyloid Systems. Journal of Physical Chemistry Letters, 2022, 13, 3586-3593.	4.6	9
78	A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways. Nature Biotechnology, 2020, 38, 1253-1256.	17.5	8
79	The Inhibitory Effect of Natural Products on Protein Fibrillation May Be Caused by Degradation Products – A Study Using Aloin and Insulin. PLoS ONE, 2016, 11, e0149148.	2.5	7
80	Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars. , 2008, , 97-111.		6
81	Self-association of long-acting insulin analogues studied by size exclusion chromatography coupled to multi-angle light scattering. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2945-2951.	2.3	6
82	Serial Coupling of Ion-Exchange and Size-Exclusion Chromatography to Determine Aggregation Levels in mAbs in The Presence of a Proteinaceous Excipient, Recombinant Human Serum Albumin. Journal of Pharmaceutical Sciences, 2015, 104, 548-556.	3.3	5
83	Influence of Tableting on the Conformation and Thermal Stability of Trypsin as a Model Protein. Journal of Pharmaceutical Sciences, 2015, 104, 4314-4321.	3.3	5
84	The dangers of citing papers you did not read or understand. Journal of Molecular Structure, 2019, 1186, 102-103.	3.6	5
85	Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution. PLoS ONE, 2022, 17, e0262537.	2.5	5
86	Lipidation Effect on Surface Adsorption and Associated Fibrillation of the Model Protein Insulin. Langmuir, 2016, 32, 7241-7249.	3.5	2
87	Manipulating Aggregation Behavior of the Uncharged Peptide Carbetocin. Journal of Pharmaceutical Sciences, 2018, 107, 838-847.	3.3	2
88	Evolving Biosimilar Clinical Requirements: A Qualitative Interview Study with Industry Experts and European National Medicines Agency Regulators. BioDrugs, 2021, 35, 351-361.	4.6	1
89	Formulation, Stability, and Characterization of Protein and Peptide Drugs. , 2004, , .		1
90	Protein pharmaceuticals. Drug Discovery Today: Technologies, 2008, 5, e35-e36.	4.0	0

ARTICLE IF CITATIONS

91 Delivery Technologies for Biopharmaceuticals: A Critical Assessment., 0,, 405-412. 0